Amphotericin B provides improved therapy for visceral leishmaniasis (VL) caused by 32 Leishmania donovani, with single dose liposomal-encapsulated Ambisome providing the best 33 cure rates. The VL elimination program aims to reduce the incidence rate in the Indian 34 subcontinent to <1/10,000 population/year. Ability to predict which asymptomatic 35 individuals (e.g. anti-leishmanial IgG and/or Leishmania-specific modified Quantiferon 36 positive) will progress to clinical VL would help in monitoring disease outbreaks. Here we 37 examined whole blood transcriptional profiles associated with asymptomatic infection, active 38 disease, and in treated cases. Two independent microarray experiments were performed, with 39 analysis focussed primarily on differentially expressed genes (DEGs) concordant across both 40 experiments. No DEGs were identified for IgG or Quantiferon positive asymptomatic groups 41 compared to negative healthy endemic controls. We therefore concentrated on comparing 42 concordant DEGs from active cases with all healthy controls, and in examining differences in 43 the transcriptome following different regimens of drug treatment. In these comparisons 6 44 major themes emerged: (i) expression of genes and enrichment of gene sets associated with 45 erythrocyte function in active cases; (ii) strong evidence for enrichment of gene sets involved 46 in cell cycle in comparing active cases with healthy controls; (iii) identification of IFNG 47 encoding interferon- as the major hub gene in concordant gene expression patterns across 48 experiments comparing active cases with healthy controls or with treated cases; (iv) 49 enrichment for interleukin signalling (IL-1/3/4/6/7/8) and a prominent role for CXCL10/9/11 50 and chemokine signalling pathways in comparing active cases with treated cases; (v) the 51 novel identification of Aryl Hydrocarbon Receptor signalling as a significant canonical 52 pathway when comparing active cases with healthy controls or with treated cases; and (vi) 53 global expression profiling support for more effective cure at day 30 post-treatment with a 3 54 single dose of liposomal encapsulated amphotericin B compared to multi-dose non-liposomal 55 amphotericin B treatment over 30 days. (296 words; 300 words allowed) 56 57 Author Summary 58 Visceral leishmaniasis (VL), also known as kala-azar, is a potentially fatal disease caused by 59 intracellular parasites of the Leishmania donovani species complex. VL is a serious public 60 health problem in rural India, causing high morbidity and mortality, as well as major costs to 61 local and national health budgets. Amphotericin B provides improved therapy for VL with 62 single dose liposomal-encapsulated Ambisome, now affordable through WHO-negotiated 63
with, both active cases and control/asymptomatic groups in experiment 1 but showed greater 241 overlap with control/asymptomatic groups in experiment 2 (cf. below). This is particularly 242 apparent when comparing plots of PC1 by PC3 ( Fig 1B and 1E ). Unsupervised hierarchical 243 cluster analysis also ( Fig 1C and 1F ) provided discrete clusters of active cases compared to 244 control and asymptomatic individuals, with treated cases interspersed with both active cases 245 and control groups and not falling into a single discrete cluster in either experiment. 246 Consistent with the PCA plots (Fig 1) , there were no differentially expressed probes 247 representing genes (i.e. Benjamini-Hochberg [25] P adj 0.05) when comparing either 248 modified quantiferon positive asymptomatic individuals with endemic healthy controls, or 249 when comparing high antibody titer individuals with endemic healthy controls, in either 250 experiment 1 or experiment 2 (data not shown). These groups were therefore analysed as one group referred to as "controls" or "healthy controls" in all further differential expression 252 analyses. 253 Differential expression analysis focused on the comparison of (i) active VL cases versus 254 controls, (ii) treated VL cases versus controls, and (iii) active versus treated VL cases. Log 2 -255 fold-change in experiment 1 was highly correlated with log 2 -fold-change in experiment 2 256 across all probes (data not shown). Table 1 shows the number of differentially expressed and 42 concordant probes for these comparisons, respectively.
264
Of note, we found a greater number of transcriptional differences between treated cases and 265 controls in experiment 1 compared to experiment 2 ( probes are 654 and 1317, respectively, at P adj ≤0.05), in which patients have received a more 275 efficacious therapy. These findings agree with the PCA results (Fig 1) , in which treated cases of the experiment 1 cohort form a more discrete group between active cases and controls (Fig 277 1A and 1B) whereas treated cases of the experiment 2 cohort are grouped more closely to 278 controls ( Fig 1D and 1E) . 279 Due to the small number of concordant differentially expressed genes identified for the 280 treated cases versus controls ( Heatmaps were generated for individual expression levels for probes representing the top 10 288 concordant genes expressed at a higher ("induced") level (Fig 2A) , and the top 10 concordant 289 genes expressed at a lower ("repressed") level ( Fig 2B) , in active cases compared to controls 290 in experiment 1. Heatmaps for the same "induced" and "repressed" probes/genes in 291 experiment 2 are presented in Fig 2C and 2D . Of note 8/10 "repressed" genes were also in 292 the top 10 most highly differentially expressed "repressed" genes in experiment 2; all 10 293 genes achieved 2-fold change in both experiments. Amongst these 10 most "repressed" 294 genes were: peptidase inhibitor 3 (PI3), a known antimicrobial peptide for bacteria and fungi To gain a more global picture of the impact of differential gene expression, the 391 genes 318 represented by 439 probes that were concordant for differential gene expression (P adj 0.05; 319 2-fold change) between active cases and controls in experiments 1 and 2 were taken forward 320 in Ingenuity Pathway (IPA) and gene-set enrichment (Enrichr) analyses. IPA network 321 analysis indicated that 254 of these genes are joined in a single network (Fig 3) , with IFNG as 322 the major hub gene (i.e. with most connections to other genes in the network), and other 
Identification of Mitotic Roles of Polo-Like Kinases as a top canonical pathway is indicative
and 5D). In this case, 6/10 and 7/10 top genes from experiment 1 were also in the top 10 377 most highly differentially expressed genes for "induced" and "repressed" gene sets in 378 experiment 2, respectively, and all achieved fold-change >2 in both experiments. Amongst 379 the 10 most "repressed" genes in experiments 1 and 2 were 3 genes also observed in the 380 comparison of active cases with healthy controls: peptidase inhibitor 3 (PI3), as noted above well known for its role in macrophage activation for anti-leishmanial activity; and GBP1 that 395 encodes a guanylate binding protein induced by interferon.
396
As there were only 42 concordant genes that achieved 2-fold change in expression, a 397 more global picture of the impact of differential gene expression was obtained by performing 398 IPA and Enrichr analyses using the full set of 210 genes represented by 221 probes that were 399 concordant for differential gene expression at P adj 0.05. IPA network analysis indicated that (i.e. with most connections to other genes in the network), and other major hub genes expressed between active cases and treated cases in experiment 2 but not experiment 1 were 427 the same genes that were most repressed in the concordant genes comparing active cases with 428 healthy controls. In comparison, 0/10 of the top "repressed" genes identified as differentially 429 expressed between active cases and treated cases in experiment 1 (but not experiment 2) 430 matched the comparison of concordant genes for active cases and healthy controls. That is, 431 treated cases in experiment 2 were behaving more like healthy controls than were treated 432 cases in experiment 1.
433
To gain a more global picture of differential gene expression that might inform 434 mechanistic differences in cure rates between the two therapeutic regimes, the 417 genes 435 (from 443 probes) that were differentially expressed between active cases and treated cases in 436 experiment 1 but not experiment 2, and the 988 genes (from 1096 probes) that were 437 differentially expressed between active cases and treated cases in experiment 2 but not 438 experiment 1, were analysed in Enrichr for gene-set enrichment. S4 Table and S5 Table   439 present details of the pathways and gene sets that contrast molecular events that characterise 440 the two different treatment groups. These are summarised in Table 3 . For the 988 genes that 441 were differentially expressed between active cases and treated cases in experiment 2 but not 442 in experiment 1 (S4 Table) Table) , with CDK1 again identified as the top PPI Hub Protein 449 for this gene set (S5 Table) . Consistent with an enhanced rate of cure, multiple immune 450 response signalling pathways (Table 3 and S4 Table) were also identified in this gene set, 
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Of note, IL-4 was identified as the most significantly down-regulated perturbed ligand 457 pathway (LINCS_L1000_Perturbed_Down; Z-score -1.8, P adj 6.36x10 -11 ) in this set of genes 458 differentially expressed in active versus treated cases in experiment 2 but not experiment 1.
459
None of these databases showed significant gene set enrichment when interrogated with the 460 417 genes identified as differentially expressed between active cases and treated controls in 461 experiment 1 but not in experiment 2, i.e. they are not present in Table 3 or S5 Table which 462 compare other enriched gene sets showing differences of interest between experiments 1 and 463 2. For example, all PPI Hub Proteins identified as significant for the 988 genes that were 464 differentially expressed between active cases and treated cases in experiment 2 but not 465 experiment 1 were related to cell cycle (S5 Table) . In contrast, the 5 significant matches to In this study we have analysed whole blood transcriptomic data to further understand the 487 pathogenesis of VL. One original goal of the study was to identify transcriptomic signatures 488 that might differentiate asymptomatic infections from uninfected controls. In our attempt to 489 achieve this we compared both modified quantiferon positive asymptomatic individuals and 490 high antibody positive asymptomatic individuals with healthy endemic controls who were 491 negative for these assays. In the event, we did not find signatures that would be diagnostic 492 for either of these asymptomatic groups compared to negative controls. This was despite Enrichr results for 417 genes differentially expressed between active VL cases and treated 646 VL cases in experiment 1 but not experiment 2, with additional gene sets (see also S4 Table) 647 enriched between active VL cases and treated VL cases in experiment 2 but not experiment 1. 
